IDiyas

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 11931343 B1

PDFFull Text
Date of Patent:
Mar. 19, 2024

Filed:

Aug. 26, 2019

Cd73 inhibitors

Applicant:

Arcus Biosciences, Inc., Hayward, CA (US);

Inventors:

Joel Beatty, San Mateo, CA (US);

Laurent Pierre Paul Debien, San Francisco, CA (US);

Samuel Lawrie Drew, Millbrae, CA (US);

Jeremy Fournier, Fremont, CA (US);

Rebecca Louise Grange, Union City, CA (US);

Steven Donald Jacob, Oakland, CA (US);

Jenna Leigh Jeffrey, Oakland, CA (US);

Kenneth V. Lawson, San Francisco, CA (US);

Manmohan Reddy Leleti, Dublin, CA (US);

Erick Allen Lindsey, San Diego, CA (US);

Debashis Mandal, Fremont, CA (US);

Jay Patrick Powers, Pacifica, CA (US);

Anh Thu Tran, Union City, CA (US);

Rhiannon Thomas-Tran, San Jose, CA (US);

Xuelei Yan, Foster City, CA (US);

Assignee:

Arcus Biosciences, Inc., Hayward, CA (US);

Attorney:

Sheppard Mullin Richter & Hampton LLP

Primary Examiner:

Valerie Rodriguez-Garcia

Assistant Examiner:

David M Shim

Int. Cl.
CPC ...
A61K 31/4192 (2006.01); A61K 31/282 (2006.01); A61K 31/422 (2006.01); A61K 31/423 (2006.01); A61K 31/437 (2006.01); A61K 31/4439 (2006.01); A61K 31/4985 (2006.01); A61K 31/519 (2006.01); A61K 31/704 (2006.01); A61K 33/243 (2019.01); A61K 39/395 (2006.01); C07D 401/14 (2006.01); C07D 403/04 (2006.01); C07D 403/14 (2006.01); C07D 405/14 (2006.01); C07D 413/14 (2006.01); C07D 471/04 (2006.01); C07D 487/04 (2006.01);
U.S. Cl.
CPC ...
A61K 31/4192 (2013.01); A61K 31/282 (2013.01); A61K 31/422 (2013.01); A61K 31/423 (2013.01); A61K 31/437 (2013.01); A61K 31/4439 (2013.01); A61K 31/4985 (2013.01); A61K 31/519 (2013.01); A61K 31/704 (2013.01); A61K 33/243 (2019.01); A61K 39/3955 (2013.01); C07D 401/14 (2013.01); C07D 403/04 (2013.01); C07D 403/14 (2013.01); C07D 405/14 (2013.01); C07D 413/14 (2013.01); C07D 471/04 (2013.01); C07D 487/04 (2013.01);
Abstract

Compounds, such as compounds having Formula (I): wherein each variable is as described herein, that modulate the conversion of AMP to adenosine by 5′-nucleotidase, ecto, and compositions containing the compounds and methods for synthesizing the compounds, are described herein. The use of such compounds and compositions for the treatment and/or prevention of a diverse array of diseases, disorders and conditions, including cancer- and immune-related disorders, that are mediated by 5′-nucleotidase, ecto is also provided.

Find Patent Forward Citations

Loading…